XML 68 R56.htm IDEA: XBRL DOCUMENT v3.25.3
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 191 Months Ended
May 11, 2025
Nov. 30, 2009
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Dec. 31, 2024
License Agreements                  
Contract dispute settlement     $ 0   $ 0 $ 242,251 $ 0    
Total revenues     1,365,980   1,137,871 3,634,407 3,062,519    
United States                  
License Agreements                  
Total revenues     1,261,261   1,070,040 3,375,171 2,887,233    
JAKAFI                  
License Agreements                  
Total revenues     791,071   741,181 2,264,271 2,018,993    
Novartis | JAKAFI                  
License Agreements                  
Royalties payable       $ 537,100          
Litigation settlement, amount awarded to other party $ 280,000                
Royalty rate payable, percent reduction (as a percent) 50.00%                
Decrease in royalties payable       $ 14,900          
Contract dispute settlement           242,200      
Novartis | JAKAFI | United States                  
License Agreements                  
Royalties payable     19,400     19,400   $ 19,400 $ 507,400
Total revenues     19,300   36,300 67,800 93,900    
Novartis | JAKAVI                  
License Agreements                  
Total revenues     125,600   115,700 327,500 304,700    
Novartis | TABRECTA                  
License Agreements                  
Total revenues     $ 6,500   $ 5,900 $ 19,600 $ 16,500    
Maximum | Novartis | JAKAVI                  
License Agreements                  
Royalty payments on future global net sales (as a percent)           14.00%      
Minimum | Novartis | JAKAVI                  
License Agreements                  
Royalty payments on future global net sales (as a percent)           12.00%      
Development Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               157,000  
Development Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   $ 174,000              
Regulatory Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               345,000  
Regulatory Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   495,000              
Commercialization Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               $ 200,000  
Commercialization Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   500,000              
Development and Regulatory Milestones | Maximum | Novartis | GVHD                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   $ 75,000